Cyramza, key to Lilly’s oncology hopes, comes through in colorectal cancer

Damian Garde

Eli Lilly's (ramucirumab) met its primary endpoint in a study on metastatic , good news for a key cog in the drugmaker's plans to capitalize on .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS